DPP-IV阻害剤の世界市場

DPP-IV阻害剤の世界市場は2030年までに147億米ドルに到達

2023年に130億米ドルと推定されるDPP-IV阻害剤の世界市場は、2023年から2030年にかけてCAGR 1.7%で成長し、2030年には147億米ドルに達すると予測されます。

米国市場は34億米ドル、中国はCAGR 1.7%で成長予測

米国のDPP-IV阻害剤市場は2023年に34億米ドルと推定されます。世界第2位の経済大国である中国は、2030年までに24億米ドルの市場規模に達すると予測され、分析期間2023-2030年のCAGRは1.7%です。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ1.6%と1.4%と予測されています。欧州では、ドイツがCAGR 2.0％で成長すると予測されています。

DPP-IV阻害剤-主要動向と促進要因

ジペプチジルペプチダーゼ-4（DPP-IV）阻害薬は、2型糖尿病の治療に用いられる経口血糖降下薬の一種です。これらの阻害剤は、グルカゴン様ペプチド-1（GLP-1）などのインクレチンホルモンを分解する役割を持つDPP-IV酵素を阻害することによって作用します。この酵素を阻害することで、DPP-IV阻害剤はインクレチンホルモンのレベルを上昇させ、食事に対するインスリンの分泌を高め、グルカゴンの放出を抑えます。この2つの作用により、血糖値を効果的に下げることができます。一般的に処方されるDPP-IV阻害剤には、シタグリプチン、サキサグリプチン、リナグリプチン、アログリプチンなどがあり、通常、他の抗糖尿病薬と併用するか、他の治療が適さない場合に単剤で使用されます。これらの薬剤は、その有効性、低血糖のリスクが比較的低いこと、注射療法よりも経口投与が多くの患者に好まれることなどから人気を博しています。

DPP-IV阻害剤市場には、いくつかの動向や開拓が影響を与えています。重要な動向の1つは、高齢化、座りがちなライフスタイル、肥満率の上昇などの要因によって、世界的に2型糖尿病の有病率が増加していることです。このような糖尿病患者の急増は、DPP-IV阻害剤のような効果的で便利な治療オプションへの需要を押し上げています。さらに、現在進行中の研究開発により、有効性と安全性のプロファイルが強化された、新しく改良されたDPP-IV阻害剤のイントロダクションがもたらされています。また、製薬会社はDPP-IV阻害剤とナトリウムグルコース共輸送体-2（SGLT-2）阻害薬やメトホルミンなどの他の抗糖尿病薬との併用療法を検討し、より包括的な血糖コントロールを行っています。さらに、遺伝的、環境的、生活習慣的要因に基づいて個々の患者のプロファイルに合わせた治療を行う個別化医療が重視されるようになってきています。このアプローチにより、DPP-IV阻害剤の効果が最適化され、副作用が最小限に抑えられると期待されています。

DPP-IV阻害剤市場の成長は、いくつかの要因によってもたらされます。創薬と薬剤開発における技術の進歩により、より強力で選択的なDPP-IV阻害剤の創製が可能になり、患者の転帰が改善されています。新興国を中心とした2型糖尿病の世界の有病率の上昇が、これらの薬剤の市場を拡大しています。糖尿病管理と最適な血糖値を維持することの重要性に対する意識の高まりが、より多くの患者に治療を求めるよう促し、DPP-IV阻害剤の需要を押し上げています。さらに、経口投与の利便性とDPP-IV阻害剤の比較的良好な副作用プロファイルが、患者やヘルスケアプロバイダーの間でDPP-IV阻害剤の採用を促進しています。また、製薬企業間の戦略的提携やパートナーシップもイノベーションを促進し、新製品の市場導入を促進しています。さらに、多くの国々における政府の支援政策や償還の枠組みにより、これらの治療がより多くの患者にとって利用しやすくなっており、市場成長の原動力となっています。

調査対象企業の例（注目の16社）

• AstraZeneca Plc.
• Boehringer Ingelheim GmbH
• Eli Lilly and Company
• Merck & Co. Inc.
• Mitsubishi Tanabe Pharma Corporation
• Novartis AG
• Takeda Pharmaceutical Company Limited

目次

第1章 調査手法

第2章 エグゼクティブサマリー

• 市場概要
• 主要企業
• 市場動向と促進要因
• 世界市場の見通し

第3章 市場分析

• 米国
• カナダ
• 日本
• 中国
• 欧州
• フランス
• ドイツ
• イタリア
• 英国
• その他欧州
• アジア太平洋
• 世界のその他の地域

第4章 競合

Global DPP-IV Inhibitors Market to Reach US$14.7 Billion by 2030

The global market for DPP-IV Inhibitors estimated at US$13.0 Billion in the year 2023, is expected to reach US$14.7 Billion by 2030, growing at a CAGR of 1.7% over the analysis period 2023-2030.

The U.S. Market is Estimated at US$3.4 Billion While China is Forecast to Grow at 1.7% CAGR

The DPP-IV Inhibitors market in the U.S. is estimated at US$3.4 Billion in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$2.4 Billion by the year 2030 trailing a CAGR of 1.7% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.6% and 1.4% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 2.0% CAGR.

DPP-IV Inhibitors - Key Trends and Drivers

Dipeptidyl peptidase-4 (DPP-IV) inhibitors are a class of oral hypoglycemic agents used to treat type 2 diabetes mellitus. These inhibitors work by blocking the DPP-IV enzyme, which is responsible for degrading incretin hormones such as glucagon-like peptide-1 (GLP-1). By inhibiting this enzyme, DPP-IV inhibitors increase the levels of incretin hormones, thereby enhancing the secretion of insulin in response to meals and reducing the release of glucagon. This dual action helps to lower blood glucose levels effectively. Commonly prescribed DPP-IV inhibitors include sitagliptin, saxagliptin, linagliptin, and alogliptin, which are typically used in combination with other antidiabetic medications or as monotherapy when other treatments are not suitable. These drugs have gained popularity due to their efficacy, relatively low risk of hypoglycemia, and oral administration, which is preferred by many patients over injectable therapies.

Several trends and developments are influencing the DPP-IV inhibitors market. One significant trend is the increasing prevalence of type 2 diabetes globally, driven by factors such as aging populations, sedentary lifestyles, and rising obesity rates. This surge in diabetes cases is boosting demand for effective and convenient treatment options like DPP-IV inhibitors. Additionally, ongoing research and development are leading to the introduction of new and improved DPP-IV inhibitors with enhanced efficacy and safety profiles. Pharmaceutical companies are also exploring combination therapies that pair DPP-IV inhibitors with other antidiabetic drugs, such as sodium-glucose co-transporter-2 (SGLT-2) inhibitors and metformin, to provide more comprehensive blood sugar control. Furthermore, there is a growing emphasis on personalized medicine, where treatments are tailored to individual patient profiles based on genetic, environmental, and lifestyle factors. This approach is expected to optimize the effectiveness of DPP-IV inhibitors and minimize adverse effects.

The growth in the DPP-IV inhibitors market is driven by several factors. Technological advancements in drug discovery and development are enabling the creation of more potent and selective DPP-IV inhibitors, improving patient outcomes. The rising global prevalence of type 2 diabetes particularly in emerging economies is expanding the market for these medications. Increasing awareness about diabetes management and the importance of maintaining optimal blood glucose levels is encouraging more patients to seek treatment, boosting demand for DPP-IV inhibitors. Additionally, the convenience of oral administration and the relatively favorable side effect profile of DPP-IV inhibitors are driving their adoption among patients and healthcare providers. Strategic collaborations and partnerships among pharmaceutical companies are also fostering innovation and facilitating the introduction of new products to the market. Furthermore, supportive government policies and reimbursement frameworks in many countries are making these treatments more accessible to a broader patient population, thereby driving market growth.

Select Competitors (Total 16 Featured) -

• AstraZeneca Plc.
• Boehringer Ingelheim GmbH
• Eli Lilly and Company
• Merck & Co. Inc.
• Mitsubishi Tanabe Pharma Corporation
• Novartis AG
• Takeda Pharmaceutical Company Limited

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

• 1. MARKET OVERVIEW
  • Influencer Market Insights
  • Global Economic Update
  • DPP-IV Inhibitors - Global Key Competitors Percentage Market Share in 2024 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
• 2. FOCUS ON SELECT PLAYERS
• 3. MARKET TRENDS & DRIVERS
  • Increasing Prevalence of Type 2 Diabetes Propels Growth in DPP-IV Inhibitors Market
  • Advancements in Drug Discovery Strengthen Business Case for Enhanced DPP-IV Inhibitors
  • Rising Obesity Rates and Sedentary Lifestyles Expand Addressable Market Opportunity
  • Growing Emphasis on Personalized Medicine Drives Adoption of Tailored DPP-IV Inhibitor Therapies
  • Development of Combination Therapies Spurring Growth in Comprehensive Diabetes Management Solutions
  • Innovations in DPP-IV Inhibitors Improve Efficacy and Safety Profiles
  • Increasing Awareness about Diabetes Management Drives Demand for Effective Treatments
  • Convenience of Oral Administration Strengthens Market Position of DPP-IV Inhibitors
  • Favorable Side Effect Profile of DPP-IV Inhibitors Propels Growth among Patient Populations
  • Advances in Clinical Research Throw the Spotlight on Next-Generation DPP-IV Inhibitors
  • Lifestyle Changes and Aging Populations Drive Adoption of Diabetes Management Solutions
  • Increasing Investment in R&D Accelerates Innovation in DPP-IV Inhibitors Market
  • Integration of Digital Health Solutions Expands Addressable Market for Diabetes Treatments
• 4. GLOBAL MARKET PERSPECTIVE
  • TABLE 1: World DPP-IV Inhibitors Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
  • TABLE 2: World Recent Past, Current & Future Analysis for DPP-IV Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 3: World 7-Year Perspective for DPP-IV Inhibitors by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2024 & 2030

III. MARKET ANALYSIS

• UNITED STATES
  • DPP-IV Inhibitors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
  • TABLE 4: USA Recent Past, Current & Future Analysis for DPP-IV Inhibitors by Segment - DPP-IV Inhibitors - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
• CANADA
  • TABLE 5: Canada Recent Past, Current & Future Analysis for DPP-IV Inhibitors by Segment - DPP-IV Inhibitors - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
• JAPAN
  • DPP-IV Inhibitors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
  • TABLE 6: Japan Recent Past, Current & Future Analysis for DPP-IV Inhibitors by Segment - DPP-IV Inhibitors - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
• CHINA
  • DPP-IV Inhibitors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
  • TABLE 7: China Recent Past, Current & Future Analysis for DPP-IV Inhibitors by Segment - DPP-IV Inhibitors - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
• EUROPE
  • DPP-IV Inhibitors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
  • TABLE 8: Europe Recent Past, Current & Future Analysis for DPP-IV Inhibitors by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 9: Europe 7-Year Perspective for DPP-IV Inhibitors by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2024 & 2030
• FRANCE
  • DPP-IV Inhibitors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
  • TABLE 10: France Recent Past, Current & Future Analysis for DPP-IV Inhibitors by Segment - DPP-IV Inhibitors - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
• GERMANY
  • DPP-IV Inhibitors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
  • TABLE 11: Germany Recent Past, Current & Future Analysis for DPP-IV Inhibitors by Segment - DPP-IV Inhibitors - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
• ITALY
  • TABLE 12: Italy Recent Past, Current & Future Analysis for DPP-IV Inhibitors by Segment - DPP-IV Inhibitors - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
• UNITED KINGDOM
  • DPP-IV Inhibitors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
  • TABLE 13: UK Recent Past, Current & Future Analysis for DPP-IV Inhibitors by Segment - DPP-IV Inhibitors - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
• REST OF EUROPE
  • TABLE 14: Rest of Europe Recent Past, Current & Future Analysis for DPP-IV Inhibitors by Segment - DPP-IV Inhibitors - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
• ASIA-PACIFIC
  • DPP-IV Inhibitors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
  • TABLE 15: Asia-Pacific Recent Past, Current & Future Analysis for DPP-IV Inhibitors by Segment - DPP-IV Inhibitors - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
• REST OF WORLD
  • TABLE 16: Rest of World Recent Past, Current & Future Analysis for DPP-IV Inhibitors by Segment - DPP-IV Inhibitors - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR

IV. COMPETITION